Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
19,020,517
-
Total 13F shares
-
9,456,135
-
Share change
-
+6,508,186
-
Total reported value
-
$69,598,197
-
Put/Call ratio
-
102%
-
Price per share
-
$7.36
-
Number of holders
-
68
-
Value change
-
+$47,945,529
-
Number of buys
-
45
-
Number of sells
-
14
Institutional Holders of Karyopharm Therapeutics Inc. - COMMON STOCK (KPTI) as of Q4 2025
As of 31 Dec 2025,
Karyopharm Therapeutics Inc. - COMMON STOCK (KPTI) was held by
68 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,456,135 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., Opaleye Management Inc., Affinity Asset Advisors, LLC, VANGUARD GROUP INC, Ikarian Capital, LLC, Soleus Capital Management, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., Davidson Kempner Capital Management LP, BRAIDWELL LP, and Exome Asset Management LLC.
This page lists
68
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.